The global extracellular matrix patches market accounted for USD 30.8 million in 2023 and is expected to reach at USD 70.6 million by 2034 with a CAGR of 7.83% during the forecast period 2024-2034. Rising prevalence of congenital heart disease (CHD) & trauma injuries, increasing number of hernia & pelvic reconstruction surgeries, growing emphasis on developing extracellular matrix solutions for pelvic reconstruction & hernia repair, surge in technological advancements in extracellular matrix applications for soft tissue repair & wound healing procedures, growing recognition of the advantages of biological patches compared to synthetic ones, and an uptick in approvals by regulatory authorities for new platforms are some of the key factors boosting the market growth.
An uptick in approvals by regulatory authorities for new platforms is predicted to boost the market growth during the forecast period. Another alternative for arterial patching is biologic extracellular matrix (ECM) patches. These patches are crafted from porcine small intestinal submucosa (SIS) through the removal of the mucosa and muscle layers. The ECM consists of collagen and other ECM components, such as growth factors. For instance, in May 2022, Ortho Regenerative Technology, a clinical-stage company specializing in orthobiologics, has been granted a patent by the United States Patent and Trademark Office for its ORTHO-R soft tissue repair platform.
By raw material, porcine was the highest revenue-grossing segment in the global extracellular matrix patches market in 2023 owing to the wide availability of these grafts, growing utilization of these grafts in repair & reconstructive surgeries due to their similarity to human collagen, which minimizes the risk of allergic reactions, and increasing introduction of new products. For instance, in October 2022, Pion Inc., a healthcare company, has created and launched the ECM-XR, a novel artificial extracellular matrix (ECM), aimed at expediting formulation development with reduced dependence on in vivo testing. Additionally, bovine is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of bovine-based products, the abundant availability of cattle, rising number of research studies, substantial investments in research & development, and growing emphasis on the development of extracellular matrix (ECM) grafts.
By application, soft tissue repair was the highest revenue-grossing segment in the global extracellular matrix patches market in 2023 owing to the increase in the number of hernia repair surgeries, especially inguinal hernia procedures, rising prevalence of trauma surgeries, healthcare providers are becoming increasingly aware of the potential of extracellular matrix applications, and surge in mergers and acquisitions among industry leaders. For instance, in August 2022, CONMED Corporation has completed the acquisition of Biorez, Inc., a privately-held company. Biorez specializes in enhancing the recovery of soft tissue through its unique BioBrace implant technology. This implant serves as a pioneering bioinductive scaffold designed to strengthen weakened soft tissue areas and promote healing. Additionally, v ascular repair & reconstruction is predicted to grow at the fastest CAGR during the forecast period owing to the rising number of vascular surgeries, increase in the prevalence of vascular diseases, growing elderly population, and heightened research & development efforts in the field.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising occurrence of cardiovascular diseases & defects, sports injuries, & trauma cases, the presence of cutting-edge research laboratories, and surge in regulatory approvals. For instance, in March 2023, The Food and Drug Administration of the United States has approved Convatec's InnovaBurn placental extracellular matrix medical device, which is designed to treat difficult surgical wounds and burns, including partial-thickness second-degree burns. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cardiovascular diseases, rise in trauma cases, surge in the number of surgeries performed, increasing healthcare expenditure, increasing allocation of research funds, and rising collaborations among market leaders. For instance, in February 2023, Baxter, a healthcare corporation, has teamed up with Miromatrix Medical Inc., a biotechnology company, to collaborate on developing a treatment for patients with acute liver failure (ALF). In this partnership, Miromatrix Medical Inc.'s single-use bioengineered liver will be combined with Baxter's PrisMax system, which is tailored to deliver personalized therapies to patients.
An uptick in approvals by regulatory authorities for new platforms is predicted to boost the market growth during the forecast period. Another alternative for arterial patching is biologic extracellular matrix (ECM) patches. These patches are crafted from porcine small intestinal submucosa (SIS) through the removal of the mucosa and muscle layers. The ECM consists of collagen and other ECM components, such as growth factors. For instance, in May 2022, Ortho Regenerative Technology, a clinical-stage company specializing in orthobiologics, has been granted a patent by the United States Patent and Trademark Office for its ORTHO-R soft tissue repair platform.
By raw material, porcine was the highest revenue-grossing segment in the global extracellular matrix patches market in 2023 owing to the wide availability of these grafts, growing utilization of these grafts in repair & reconstructive surgeries due to their similarity to human collagen, which minimizes the risk of allergic reactions, and increasing introduction of new products. For instance, in October 2022, Pion Inc., a healthcare company, has created and launched the ECM-XR, a novel artificial extracellular matrix (ECM), aimed at expediting formulation development with reduced dependence on in vivo testing. Additionally, bovine is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of bovine-based products, the abundant availability of cattle, rising number of research studies, substantial investments in research & development, and growing emphasis on the development of extracellular matrix (ECM) grafts.
By application, soft tissue repair was the highest revenue-grossing segment in the global extracellular matrix patches market in 2023 owing to the increase in the number of hernia repair surgeries, especially inguinal hernia procedures, rising prevalence of trauma surgeries, healthcare providers are becoming increasingly aware of the potential of extracellular matrix applications, and surge in mergers and acquisitions among industry leaders. For instance, in August 2022, CONMED Corporation has completed the acquisition of Biorez, Inc., a privately-held company. Biorez specializes in enhancing the recovery of soft tissue through its unique BioBrace implant technology. This implant serves as a pioneering bioinductive scaffold designed to strengthen weakened soft tissue areas and promote healing. Additionally, v ascular repair & reconstruction is predicted to grow at the fastest CAGR during the forecast period owing to the rising number of vascular surgeries, increase in the prevalence of vascular diseases, growing elderly population, and heightened research & development efforts in the field.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising occurrence of cardiovascular diseases & defects, sports injuries, & trauma cases, the presence of cutting-edge research laboratories, and surge in regulatory approvals. For instance, in March 2023, The Food and Drug Administration of the United States has approved Convatec's InnovaBurn placental extracellular matrix medical device, which is designed to treat difficult surgical wounds and burns, including partial-thickness second-degree burns. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cardiovascular diseases, rise in trauma cases, surge in the number of surgeries performed, increasing healthcare expenditure, increasing allocation of research funds, and rising collaborations among market leaders. For instance, in February 2023, Baxter, a healthcare corporation, has teamed up with Miromatrix Medical Inc., a biotechnology company, to collaborate on developing a treatment for patients with acute liver failure (ALF). In this partnership, Miromatrix Medical Inc.'s single-use bioengineered liver will be combined with Baxter's PrisMax system, which is tailored to deliver personalized therapies to patients.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Extracellular Matrix Patches Market Report 2023 - 2034
Extracellular Matrix Patches Market Analysis & Forecast by Raw Material 2023 - 2034 (Revenue USD Mn)
- Porcine
- Bovine
- Others
Extracellular Matrix Patches Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Vascular Repair & Reconstruction
- Dural Repair
- Cardiac Repair
- Wound Healing
- Soft Tissue Repair
- Pericardial Repair
Extracellular Matrix Patches Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Extracellular Matrix Patches Market: Raw Material Estimates & Trend Analysis
8. Extracellular Matrix Patches Market: Application Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Extracellular Matrix Patches Market
11. Europe Extracellular Matrix Patches Market
12. Asia Pacific Extracellular Matrix Patches Market
13. Latin America Extracellular Matrix Patches Market
14. MEA Extracellular Matrix Patches Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Coloplast Group
- Aziyo Biologics
- Smith & Nephew
- Cook Group
- MTF Biologics
- Medtronic
- Koninklijke DSM N.V.
- Baxter
- Admedus Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 30.8 Million |
| Forecasted Market Value ( USD | $ 70.6 Million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
